Skip to main content

Advertisement

SpringerLink
Log in

Aromatase Inhibitor Adjuvant Chemotherapy of Breast Cancer Results in Cancer Therapy Induced Bone Loss

  • Current Therapeutics (SL Silverman, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Aromatase Inhibitors are anti-estrogen agents that have proven efficacy for adjuvant therapy of estrogen receptor positive breast cancer primarily in post menopausal women with estrogen receptor positive breast cancer but increase the risk of cancer therapy induced bone loss (CTIBL). Recent studies have shown the potential benefit of bisphosphonate therapy to play a dual role in the management of breast cancer. These studies provide evidence that bisphosphonate therapy in conjunction with aromatase inhibitors (AI), not only decreases the risk of osteoporosis but, in addition, may improve survival from breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Greep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;114:653.

    Article  PubMed  Google Scholar 

  2. •• Guise T, Brufsky A, Coleman R. Understanding and optimizing bone health in breast cancer. CMRO. 2010;26(3):3–20. Excellent review by lead researchers explains pathophysiology and adds perspective.

    Article  CAS  Google Scholar 

  3. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348:2431.

    Article  PubMed  CAS  Google Scholar 

  4. Lønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years vs placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23:5126.

    Article  PubMed  Google Scholar 

  5. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol. 2007;8:119.

    Article  PubMed  CAS  Google Scholar 

  6. Hadji P, Ziller M, Kieback DG, et al. Effects of exemestane and tamoxifen on bone health within the TEAM trial: results of a German, 12 month, prospective, randomized sub-study. Ann Oncol. 2009;20:1203–9.

    Google Scholar 

  7. •• Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103:1299–309. Highlights toxicity issues which could alter treatment decisions and guideline development.

  8. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829.

    Article  PubMed  CAS  Google Scholar 

  9. • Brufsky AM, Harker WG, Beck JT et al. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer. 2012;118:1192. Results of a large randomized controlled trial showing that bisphosphonate therapy improves AI induced bone loss.

  10. Brufsky AM, Bosserman LD, Caradonna RR, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9:77.

    Article  PubMed  CAS  Google Scholar 

  11. Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 2010;21:2188.

    Article  PubMed  CAS  Google Scholar 

  12. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679.

    Article  PubMed  CAS  Google Scholar 

  13. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial. Lancet Oncol. 2011;12:631.

    Article  PubMed  CAS  Google Scholar 

  14. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H. Long-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor–positive early breast cancer. 2011 CTRC-AACR San Antonio Breast Cancer Symposium, 2011;Abstract S1–2.

  15. Coleman R, Marshall H, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365:1396–405.

    Article  PubMed  CAS  Google Scholar 

  16. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26:4875.

    Article  PubMed  CAS  Google Scholar 

  17. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132.

    Article  PubMed  CAS  Google Scholar 

  18. Study of denosumab as adjuvant treatment for women with high risk early breast cancer receiving neoadjuvant or adjuvant therapy (D-CARE). NIH: NCT01077154.

  19. Morales L, Pans S, Verschueren K. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol. 2008;26(19):3147.

    Article  PubMed  Google Scholar 

  20. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042.

    Article  PubMed  CAS  Google Scholar 

  21. Body JJ, Bergmann P, Boonen S, et al. Management of cancer treatment-induced bone loss in early breast and prostate cancer – a consensus paper of the Belgian Bone Club. Osteoporos Int. 2007;18:1439.

    Article  PubMed  CAS  Google Scholar 

  22. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev. 2008;34 Suppl 1:S3.

    Article  PubMed  CAS  Google Scholar 

  23. • Rizzoli R, Body J, et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. Osteporos Int. 2012;23:2567–76. Excellent proposed guidelines for monitoring and treating AI associated bone loss.

Download references

Disclosure

The author reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Cedars Sinai Medical Center, The David Geffen School of Medicine, UCLA, 150 North Robertson Blvd, Beverly Hills, CA, 90211, USA

    Renee Z. Rinaldi

Authors
  1. Renee Z. Rinaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Renee Z. Rinaldi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rinaldi, R.Z. Aromatase Inhibitor Adjuvant Chemotherapy of Breast Cancer Results in Cancer Therapy Induced Bone Loss. Curr Osteoporos Rep 11, 61–64 (2013). https://doi.org/10.1007/s11914-013-0134-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-013-0134-7

Keywords

Search

Navigation